Quick Facts: Therapeutic Areas

• Chronic Treatment of Asthma: Used for the long-term management and prophylaxis of asthma in adult and pediatric patients.
• Exercise-Induced Bronchoconstriction (EIB): Indicated for the acute prevention of airway narrowing caused by physical activity.
• Allergic Rhinitis: May provide potential relief for symptoms associated with both seasonal and perennial (year-round) allergic rhinitis.

---

What Singulair Treats: Main Uses and Benefits

Singulair (montelukast sodium) is a prescription treatment that may be considered for the management of several respiratory and allergic conditions. It is an approved option for the chronic treatment of asthma in patients 12 months of age and older, functioning as a component of long-term control therapy. This medication is also indicated for the acute prevention of exercise-induced bronchoconstriction (EIB) in patients six years of age and older.

In the area of allergies, Singulair is used to potentially support the relief of symptoms related to allergic rhinitis. This includes both seasonal allergic rhinitis in patients two years of age and older and perennial allergic rhinitis in patients six months of age and older. Due to the potential risk of neuropsychiatric adverse reactions, the use of this medication for allergic rhinitis may be reserved for patients who have an inadequate response or intolerance to alternative therapies. It is not indicated for the management of acute asthma exacerbations or attacks.

Who Can and Cannot Use Singulair (Montelukast Sodium)

The eligibility for using Montelukast sodium is strictly defined by regulatory criteria, encompassing age, physiological status, and contraindications.

Contraindicated Populations

Montelukast is contraindicated for patients with known hypersensitivity to any component of the product. It is also prohibited for patients with rare hereditary issues such as galactose intolerance or total lactase deficiency due to excipients in the formulation. Montelukast is not indicated for use during an acute asthma attack and must not be used as an abrupt substitute for inhaled or oral corticosteroids.

Age-Specific Eligibility

Indication	Minimum Age for Established Use
Chronic Asthma	12 months
Exercise-Induced Bronchoconstriction (EIB)	6 years
Perennial Allergic Rhinitis (PAR)	6 months

Conditional Use and Restrictions

Use is highly conditional in certain groups. During pregnancy and lactation, the medicine should be used only if it is considered to be clearly essential. Furthermore, use in patients with severe hepatic impairment is not established, as the pharmacokinetics have not been evaluated. Patients with mild-to-moderate hepatic or renal impairment do not require dosage adjustments. The 4-mg and 5-mg chewable tablets contain phenylalanine and must be used with caution in patients with Phenylketonuria (PKU).

Singulair Interactions with other medicines and products

This section outlines the officially documented interactions for Singulair (montelukast sodium), based on government regulatory prescribing information.

Pharmacokinetic Interactions (Exposure Alteration)

Montelukast is metabolized primarily by Cytochrome P450 (CYP) enzymes, chiefly CYP2C8, CYP2C9, and CYP3A4. Interactions are categorized by their effect on drug exposure (Area Under the Curve, or AUC):

Interaction Type	Interacting Medicine	Official Regulatory Effect on Montelukast AUC
Decrease Exposure (Induction)	Rifampicin, Phenobarbital	Reduction by approximately 40%
Increase Exposure (Inhibition)	Gemfibrozil	Increase by approximately 4.4-fold

The official labeling notes that despite the substantial increase in exposure caused by Gemfibrozil, no routine montelukast dosage adjustment is required.

Pharmacodynamic and Population-Specific Interactions

Montelukast does not have any explicitly contraindicated drug combinations. The regulatory profile notes specific precautions:

• Aspirin and NSAIDs: Patients with a known aspirin sensitivity must continue to avoid aspirin and other NSAIDs, as montelukast does not modify the bronchoconstrictor response to these agents.
• Pediatric Patients: Caution is advised when co-administering CYP inducers (such as Phenytoin, Phenobarbital, and Rifampicin) in children due to the potential for decreased montelukast exposure.

Food Interactions

Taking the oral granule formulation with a high-fat meal reduces the maximum plasma concentration ( C max) by 35%, though the total systemic exposure (AUC) remains unchanged.

Targeted Blockade of Leukotriene Receptors

Montelukast's action is defined by a selective mechanism focused on interrupting leukotriene-mediated signaling. It functions as a selective and competitive antagonist of the Cysteinyl Leukotriene 1 Receptor ( CysLT1 receptor). This receptor serves as the primary binding site for the major inflammatory mediator Leukotriene D4 ( LTD4). By occupying the receptor, Montelukast prevents LTD4 from binding and initiating its G-protein coupled signaling cascade, thereby interrupting the signal transduction pathway triggered by leukotrienes.

Functional Modulation of Airway Smooth Muscle and Edema

The blockade of the CysLT1 receptor directly affects cell function, as LTD4 is a major bronchoconstrictor. By inhibiting this signaling, the drug prevents the contraction of airway smooth muscle cells, resulting in the functional consequence of reduced smooth muscle tone. Furthermore, this mechanism attenuates the increase in vascular permeability caused by Cysteinyl Leukotrienes ( CysLTs). This leads to a reduction in airway tissue edema and limits the migration of eosinophils into the airways. The effect is restricted to pathways primarily driven by CysLT1 signaling, as the drug does not antagonize the CysLT2 receptor.

How to Use Singulair (Montelukast)

Montelukast sodium is administered for oral use only, utilizing three distinct solid forms: the film-coated tablet, chewable tablet, and oral granules. The high-level administration protocol is defined by a consistent once-daily pattern for maintenance treatment.

---

Official Dosing and Timing Principles

The standard prescribed dose is fixed according to the patient's age and indication, with no need for titration in official guidelines.

Age Group	Daily Dosage	Form Examples
Adults (15+ years)	10 mg	Film-Coated Tablet
Pediatric (6–14 years)	5 mg	Chewable Tablet
Pediatric (6 months–5 years)	4 mg	Chewable Tablet or Granules

For chronic maintenance treatment of asthma or allergic rhinitis, the medication is generally taken once daily in the evening. The drug may be taken with or without food. However, when used for the acute prevention of exercise-induced bronchoconstriction (EIB), the single dose must be administered at least two hours before exercise, and no additional dose should be taken within 24 hours.

---

Granule Preparation Instructions

For the oral granule formulation, specific preparation is required to ensure proper administration. The entire contents of the sachet must be mixed with a small amount of cold or room temperature soft food (e.g., applesauce or mashed carrots) or dissolved in 5 mL of cold or room temperature baby formula or breast milk. The mixture must be ingested completely within 15 minutes of opening the granule packet.

Recent Clinical Evidence Overview

Montelukast, the active ingredient in Singulair, is a leukotriene receptor antagonist primarily studied for the prophylaxis and chronic treatment of asthma, the prevention of exercise-induced bronchoconstriction (EIB), and the management of allergic rhinitis (seasonal and perennial).

---

Efficacy and Treatment Role

Clinical trials, including randomized controlled trials (RCTs) and meta-analyses, have consistently supported the drug's role in improving measures of lung function and reducing symptoms in patients with persistent asthma. Montelukast is often utilized as an alternative or add-on controller therapy, particularly in children under certain age cutoffs where inhaled corticosteroids (ICS) may present challenges, or in cases where concomitant allergic rhinitis is present. However, some comparative studies and asthma guidelines suggest that inhaled corticosteroids may offer superior efficacy for primary controller therapy in many asthma patients.

---

Safety and Regulatory Warnings

Safety surveillance and post-marketing reports have prompted regulatory authorities (including the FDA and TGA) to strengthen warnings regarding potential neuropsychiatric events associated with montelukast. These reported events include mood changes, agitation, aggression, anxiety, sleep disturbances (such as nightmares), depression, and suicidal thoughts or actions.

In 2020, the U.S. FDA required a Boxed Warning to be added to the drug's label, emphasizing the risk of these serious mental health side effects. Due to this risk, the drug's use for allergic rhinitis is generally advised to be reserved for patients who have not responded adequately to, or cannot tolerate, alternative therapies.

Common questions about Singulair (FAQ)

---

Q: How long does it take for Singulair to start working for allergies?

A: Official product information indicates that the drug is rapidly absorbed into the bloodstream after being taken by mouth. The maximum amount of the drug in the blood is typically reached in about three to four hours. While this reflects how quickly the active ingredient enters your system, the full clinical effect for allergy symptom relief may vary.

Q: What are the most common side effects of Singulair?

A: According to clinical trials reviewed by regulatory authorities, the most common side effects reported were similar to placebo in many cases. Reactions reported by at least 5% of patients and more frequently than placebo included upper respiratory infection, fever, and headache.

Q: Is it true that Singulair can cause mood changes?

A: Yes, regulatory documents have been updated with a Boxed Warning to highlight the risk of serious mental health side effects. These neuropsychiatric events can include mood changes, agitation, anxiety, depression, and even suicidal thoughts or behavior. Due to these potential risks, the drug is not a first-choice treatment for allergic rhinitis.

Q: Can Singulair cause vivid dreams or nightmares?

A: Official safety data has associated the active ingredient, montelukast, with reports of dream abnormalities and nightmares. These are listed as part of the possible neuropsychiatric adverse events. Changes in sleep or dreams are part of the reported neuropsychiatric events; individuals should discuss any concerns with a healthcare professional.

Q: Does Singulair interact with common over-the-counter allergy medicines?

A: Clinical studies did not show that montelukast had any clinically significant effect on the blood levels of several other drugs. It has been used alongside many common medicines, including some decongestants, without evidence of significant harmful interactions. However, it is always helpful to let a healthcare provider know all medications being taken.

Q: What should I do if I feel dizzy after taking Singulair?

A: Dizziness was reported in clinical trials, although it occurred in a small percentage of patients. New or worsening dizziness or any other concerning side effect should be discussed with a healthcare professional, as they can provide individual guidance.

Q: Can I drink alcohol while I am taking Singulair?

A: Regulatory labeling does not list a specific interaction between montelukast and alcohol. However, since the medication can be associated with liver changes in very rare cases, excessive alcohol consumption may potentially increase the risk of liver-related issues. Individuals should discuss their alcohol consumption with their healthcare provider.

Q: What happens if you stop taking Singulair suddenly?

A: Singulair is intended for chronic, long-term maintenance treatment, and sudden cessation may lead to a return or worsening of asthma or allergy symptoms. If neuropsychiatric side effects occur, regulatory guidance advises immediate discontinuation and contact with a healthcare professional.

Q: What does the research say about Singulair's long-term safety?

A: The primary long-term safety concern that led to updated regulatory warnings is the potential for serious neuropsychiatric events, such as depression and suicidal thoughts. For the treatment of allergic rhinitis, its use is generally advised only when alternative therapies have been inadequate or not tolerated due to these safety risks.

Q: Is there a rebound effect when stopping Singulair?

A: Regulatory warnings focus on a risk of developing a condition called Churg-Strauss Syndrome (a vasculitis) if oral steroid therapy is reduced or withdrawn while starting montelukast. There is no specific rebound effect mentioned in the official label related to the cessation of montelukast alone.

Q: Can Singulair cause headaches?

A: Yes, headaches are listed as a common adverse reaction in clinical trials. They were reported in a measurable percentage of patients taking the drug.

Q: Can Singulair help with cough that is related to asthma?

A: The drug is indicated for the chronic treatment and prevention of asthma. By addressing the underlying inflammation of asthma, it may help control associated symptoms like cough.

Q: What is the evidence for Singulair's use in younger children?

A: The use and dosing for montelukast are well-established by regulatory bodies for very young patients. It is indicated for treating perennial allergic rhinitis in patients as young as 6 months and for asthma prevention in patients 12 months of age and older.

Q: Should Singulair be taken with food or on an empty stomach?

A: For the tablet and chewable forms, the medication can generally be taken either with or without food. If using the oral granule formulation, it can be mixed with a small amount of cold or room-temperature food or liquid and must be consumed within 15 minutes.

Q: Can Singulair be used for chronic hives?

A: The primary regulatory indications for this medicine are asthma and allergic rhinitis. While the drug is sometimes utilized for chronic idiopathic urticaria (hives of long duration), this use is not explicitly listed as an official regulatory indication on the main product labels in most countries.

Q: Is it okay if I occasionally forget to take my Singulair dose?

A: The recommended guidance is to skip the missed dose if you remember it later. Individuals should continue with the next scheduled dose at the regular time, avoiding taking two doses at once.

Q: Is it normal to feel a bit restless when first starting Singulair?

A: Restlessness is not specifically listed as a common side effect, but the official label mentions related serious neuropsychiatric events, including agitation and anxiety. Patients and caregivers should monitor closely for any new or worsening behavioral or mood symptoms.

Q: Can Singulair be used by athletes?

A: Yes, one of the regulatory indications for Singulair is the acute prevention of exercise-induced bronchoconstriction (EIB). This makes it a relevant treatment option for many athletes whose breathing is affected by physical exertion.

Q: Can Singulair be taken alongside blood pressure medication?

A: Montelukast has been administered alongside a wide range of commonly prescribed medications, including those for blood pressure, in clinical studies without evidence of adverse interactions. Individuals taking blood pressure medication should still have their healthcare professional review all current treatments for a comprehensive check.

Q: Can Singulair help with sinus congestion?

A: The drug is indicated for the relief of symptoms associated with allergic rhinitis (hay fever and year-round allergies). By targeting the causes of allergic rhinitis, the drug may help relieve associated symptoms like sinus congestion.

Q: Does Singulair affect fertility?

A: Studies in animals indicated no effects on fertility. However, there are not currently sufficient studies in humans to conclusively determine if the active ingredient, montelukast, affects a person's ability to conceive.

How to Store and Dispose of Singulair (Montelukast Sodium)

Storage Requirements

Singulair tablets, chewable tablets, and oral granules must be stored at Controlled Room Temperature, which is officially defined as 25 C (77 F), with allowed temperature excursions between 15 C and 30 C. The medication must be kept in the original container and protected from both light and moisture. It is required to keep the product out of the sight and reach of children and to avoid storing it in environments like the bathroom. The medication must not be frozen.

Handling and Disposal

Singulair oral granules have a specific stability constraint: if mixed with food or liquid, the entire dose must be administered within 15 minutes of opening the sachet, and any unused mixture must be discarded. Disposal of expired or unused Singulair must be done in accordance with local requirements for pharmaceutical waste, which often involves utilizing drug take-back programs.